How do bacteria eat tumors?
A new approach aims to let microbes attack cancer from the inside
Researchers are engineering bacteria to exploit the unique environment inside solid tumours — low oxygen, high nutrients and a suppressed immune response — turning microbes into targeted tumour eaters. Teams including investigators at the University of Waterloo have modified bacterial strains so that dormant spores or anaerobic bacteria can enter the tumour core, germinate or grow where oxygen is scarce, and consume local nutrients while expanding within the mass.
Laboratory results so far are preclinical. In models, these engineered microbes invade tumour tissue, proliferate in hypoxic niches that chemotherapy and immune cells often fail to reach, and degrade tumour biomass. The work aims to achieve three linked outcomes: directly reduce tumour volume, expose tumour antigens to the immune system, and act as a delivery vehicle for anti-cancer payloads (for example, enzymes or immune-stimulatory proteins).
Why this matters
- Solid tumours commonly contain regions that are poorly served by blood vessels. That makes conventional drugs less effective; microbes can access these pockets.
- If bacteria can be safely constrained to tumours, they offer a route to reach and dismantle therapy-resistant tissue.
Key challenges and next steps
- Safety: preventing uncontrolled infection or spread beyond the tumour is the top priority.
- Immune control: the host immune response may clear therapeutic bacteria before they act, or cause harmful inflammation.
- Translation: researchers need robust animal studies showing efficacy and safety, followed by carefully controlled human trials.
In short, the strategy repurposes an old biological interaction — microbes thriving in low-oxygen niches — into a potential cancer therapy. Significant safety testing and regulatory review lie ahead before this shifts from laboratory promise to clinical option.